# Eli Lilly 已以最高 2.02 億美元現金收購 Engage Biologics。

*biotech · news · 2026-05-20 · MarketScreener*

## Key points

- Eli Lilly 以最高 2.02 億美元現金收購 Engage Biologics。
- 該交易包含前期付款及依里程碑達成的額外付款。
- Engage Biologics 正在開發一種新的 DNA 傳遞系統，以解決效力及耐受性問題。
- 此次收購是 Lilly 2024 年一系列生物技術公司收購案的延續。

By Elias Schisgall Eli Lilly has acquired Engage Biologics, a preclinical biotechnology company developing a novel DNA delivery system, for up to $202 million in cash. The pharmaceutical company's financing for the acquisition includes an upfront payment, as well as subsequent payments based on development milestones, Engage said Wednesday. Engage's DNA delivery system being developed to overcome potency, tolerability, and redosability obstacles in existing DNA delivery methods, the company said. "We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine," Engage Chief Executive Will Olsen said. "We believe that the combination of Engage's platform with Lilly's significant capabilities will meaningfully accelerate development of new genetic therapies." The purchase of Engage adds to a string of acquisitions by Lilly this year. The company's recent purchases include multibillion-dollar acquisitions of Ajax Therapeutics, Kelonia Therapeutics, Centessa Pharmaceuticals and Orna Therapeutics. Write to Elias Schisgall at elias.schisgall@wsj.com (END) Dow Jones Newswires 05-20-26 1024ET

**Companies:** Eli Lilly, Engage Biologics
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/eli-lilly-buys-engage-biologics-for-up-to-202-million-ce7f5ad9da8cf42d)

---

Canonical: https://newsio.io/zh-TW/n/cbd77110-db4c-457b-8807-07ec76ead751/eli-lilly-2-02-engage-biologicsengage-dna-lilly
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works